Gossamer Bio ( (GOSS) ) has released its Q2 earnings. Here is a breakdown of the information Gossamer Bio presented to its investors.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Gossamer Bio, Inc. is a late-stage clinical biopharmaceutical company based in San Diego, California, focusing on developing and commercializing seralutinib for treating pulmonary hypertension. In its latest earnings report for the quarter ending June 30, 2025, Gossamer Bio reported a significant decrease in total revenue compared to the previous year, primarily due to the absence of revenue from the sale of licenses. The company generated $11.5 million in revenue from contracts with collaborators, a notable increase from the same period last year. However, the company faced a net loss of $38.3 million for the quarter, a stark contrast to the net income of $49.2 million reported in the same quarter of 2024. This loss is attributed to increased research and development expenses, which rose to $41.6 million, reflecting the company’s ongoing commitment to advancing its clinical programs. Despite the financial challenges, Gossamer Bio remains focused on its strategic goals, including the development of seralutinib. The company has a strong cash position, with $26.3 million in cash and cash equivalents, although this represents a decline from the previous year. Looking ahead, Gossamer Bio acknowledges the need for additional capital to sustain its operations and continue its research endeavors. The management expresses confidence in its ability to secure the necessary funding and remains committed to progressing its pipeline and achieving long-term success.